Goodbye CPAP? New sleep apnea pill cuts breathing events by 44%
A new oral medication, AD109, has shown promising results in a phase 3 clinical trial for treating obstructive sleep apnea by targeting neuromuscular drivers of airway collapse. The drug could serve as a significant alternative for patients who struggle with traditional CPAP therapy.
Why it matters
Sleep apnea is a widespread chronic condition, and an effective oral treatment could drastically improve patient compliance and health outcomes compared to current standard therapies.
A once-nightly oral medication significantly improved obstructive sleep apnea in a large phase 3 clinical trial presented at the 2026 ATS International Conference. The drug, known as AD109, is designed to treat OSA by targeting the neuromuscular problems that contribute to airway collapse during sleep.
The study, "Aroxybutynin and Atomoxetine (AD109) for Obstructive Sleep Apnea: A Randomized Phase 3 Trial," was published in the American Journal of Respiratory and Critical Care Medicine .
In the SynAIRgy trial, people who received AD109 experienced fewer interruptions in breathing, less oxygen deprivation, and better overall blood oxygen levels while they slept. More than 40 percent improved enough to move into a less severe OSA category, while 18 percent achieved complete disease control.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in